OPTISON Drug Patent Profile
✉ Email this page to a colleague
When do Optison patents expire, and when can generic versions of Optison launch?
Optison is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in OPTISON is albumin human. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the albumin human profile page.
Summary for OPTISON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 70 |
Clinical Trials: | 20 |
Patent Applications: | 2,999 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for OPTISON |
What excipients (inactive ingredients) are in OPTISON? | OPTISON excipients list |
DailyMed Link: | OPTISON at DailyMed |
Recent Clinical Trials for OPTISON
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mayo Clinic | Phase 1 |
Covance | Phase 4 |
Chiltern International Inc. | Phase 4 |
Pharmacology for OPTISON
Drug Class | Contrast Agent for Ultrasound Imaging |
Mechanism of Action | Ultrasound Contrast Activity |
Anatomical Therapeutic Chemical (ATC) Classes for OPTISON
US Patents and Regulatory Information for OPTISON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OPTISON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OPTISON
See the table below for patents covering OPTISON around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 0547126 | ⤷ Sign Up | |
European Patent Office | 0576521 | PERFECTIONNEMENTS APPORTES AUX AGENTS DE CONTRASTE (IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS) | ⤷ Sign Up |
Singapore | 54121 | Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OPTISON
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0961612 | 2009C/046 | Belgium | ⤷ Sign Up | PRODUCT NAME: PACLITAXEL ALBUMIN; AUTHORISATION NUMBER AND DATE: EU/1/07/428/001 20080111 |
1853250 | 2014C/037 | Belgium | ⤷ Sign Up | PRODUCT NAME: PACLITAXEL DANS UNE FORMULATION DE NANOPARTICULE LIEES A L'ALBUMINE; AUTHORISATION NUMBER AND DATE: EU/1/07/428 20131230 |
0961612 | SZ 41/2009 | Austria | ⤷ Sign Up | PRODUCT NAME: PACLITAXEL ALBUMIN |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |